Ustekinumab for the treatment of psoriatic arthritis.
Psoriatic arthritis occurs commonly in those with psoriasis and is associated with progressive joint destruction, physical disability, reduced quality of life and increased mortality. For many patients the currently available treatment options including the anti-TNF treatments are inadequate. Recent data suggest that ustekinumab can provide an effective treatment option in these patients. We discuss the role of ustekinumab in the treatment of psoriatic arthritis and highlight areas requiring further work.
Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
David John
DJ
Chandler
Anthony
A
Bewley
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D018450:Disease Progression; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy / Q000473:pathology; D011788:Quality of Life; D016896:Treatment Outcome; D000069549:Ustekinumab
D061067:Antibodies, Monoclonal, Humanized; D000069549:Ustekinumab